Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial
Nabil F. Saba, Conor Steuer, Asari Ekpenyong, Ashley A. McCook‐Veal, Kelly R. Magliocca, Mihir R. Patel, Nicole C. Schmitt, William A. Stokes, James E. Bates, Soumon Rudra, Jill Remick, Mark W. McDonald, Marin Abousaud, Aik Choon Tan, Muhammad Zaki Hidayatullah Fadlullah, Ritu Chaudhary, Jameel Muzaffar, Kedar Kirtane, Yuan Liu, Georgia Z. Chen, Dong M. Shin, Yong Teng, Christine H. Chung
Topics & Concepts
MedicineCabozantinibInternal medicinePembrolizumabTolerabilityClinical endpointOncologyResponse Evaluation Criteria in Solid TumorsHead and neck squamous-cell carcinomaGastroenterologyAdverse effectProgression-free survivalPhases of clinical researchSurgeryHead and neck cancerClinical trialChemotherapyCancerImmunotherapyCancer Immunotherapy and BiomarkersBrain Metastases and TreatmentLung Cancer Treatments and Mutations